about
The gut hormones in appetite regulationGLP-1-based strategies: a physiological analysis of differential mode of actionGLP-1, the gut-brain, and brain-periphery axesVaccination against GIP for the treatment of obesityThe physiological role of the brain GLP-1 system in stressGut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studiesDegradation and Stabilization of Peptide Hormones in Human Blood SpecimensEffects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated isletsResveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic controlEmerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetesEfficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits.Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis.GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese MiceN-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptorSafety of Anti-Diabetic Therapies on Bone.Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.Berry and Citrus Phenolic Compounds Inhibit Dipeptidyl Peptidase IV: Implications in Diabetes ManagementElevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional studyOvernight hypoxic exposure and glucagon-like peptide-1 and leptin levels in humans.Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Using the lymphatics to study nutrient absorption and the secretion of gastrointestinal hormones.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.Cardioprotective effects of incretin during ischaemia-reperfusion.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Peptide delivery using phospholipid micelles.Obesity and appetite controlGLP-1 effects on islets: hormonal, neuronal, or paracrine?Direct cardiovascular effects of glucagon like peptide-1.Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.Recent progress in natural products as DPP-4 inhibitors.
P2860
Q21296779-5C3EC3EF-A604-4010-A5F5-CE6D0F61BAE1Q26997149-A3AB6901-8B5D-4F3B-A020-3DB7C0673186Q27000749-CA6F292B-C90A-4EA5-96DA-C999BEE49AC8Q27300376-D5F23E84-72C8-4977-B271-C4B19D150F29Q28077787-ADF45E18-2575-4B8F-86A1-E98422E31B04Q28541879-EC88C843-66B5-4868-B53C-3A0683A65EA9Q28546842-6E3A7E95-9402-445E-8D32-E3902A4AF61DQ28573769-6F6B702B-EFFB-457B-91C3-6CAF36D66D9AQ28743932-233AB8BA-8E1F-4458-B2A2-D9E5632E722FQ28762629-31BED03F-53C9-497F-9465-653C4E33E65DQ31082841-0B4D5933-CFF1-4F8B-A229-7B301E3B2C65Q33789529-22DC9BDA-1AA5-4AAB-BC29-D181EFFA9932Q33838229-7A1B82E7-6E7C-41CE-9BD4-F4BE701DE042Q35210037-C081D6FE-3786-44C1-97ED-D9861BA8FD01Q35751190-43986840-8DD1-4165-B544-9655DD36D392Q35769544-693FBC54-EE02-44A3-B659-0FDB8A83179CQ36599662-00B25604-855E-44CE-A649-902A3B8B41BAQ36716222-D5FE5A04-C86B-4910-B363-302A9E72D0B1Q36731945-3CF57422-CE88-453F-B76C-A2FB8814720DQ36735761-982EBFE7-AD39-49C9-85AC-B43D129647CDQ37082698-65FCB0C6-9F1B-4F92-BDB0-17036B509DCDQ37171907-CE3BE9D5-0C62-4816-8042-5A48E11E64A6Q37172662-6D23132C-B49C-4092-8FCB-377809474404Q37215431-74859C52-5C3E-4A60-ACD3-298C96F31801Q37395298-A21BC66C-FA67-4135-94E9-41270B411CB5Q37556648-613ED0F3-73AD-45C4-92B4-5F55E4042FB0Q37611715-788EF6FB-4EE2-4F99-B70B-99238EA0FCF3Q37878588-3B58A146-FA3A-4F12-B1FE-13158512CF46Q37941683-BE055294-A633-4D73-97A6-F2AF1AA2E70AQ37984567-53F5AFF2-2FBA-445E-BB32-459AFE4F4C25Q38002006-2C30BF74-7DBB-469E-803F-F7C5BCB80851Q38012068-DCF16350-8B1F-4AFC-98E8-180E867897DDQ38030889-2A2FCBC8-5CA5-4B5B-B3E0-8E9BD9929C87Q38035293-F424B295-35F8-4110-93C1-D93AED327224Q38123791-AC118FC2-A155-478D-8676-D0D1FE0AC1CEQ38132470-481D2E38-E7C4-4BFF-BEF5-946A41D412E4Q38270204-740B038A-E917-498A-993C-AF0CF09534D8Q38304738-B0A7E3A6-63E4-4E32-847B-AD12199DC12BQ38378906-DD6008B8-8F7F-48AC-A0FC-BCF45976CF1FQ38524167-B0C3C29E-A296-41C9-B91A-C367DB6881EE
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Circulation and degradation of GIP and GLP-1.
@ast
Circulation and degradation of GIP and GLP-1.
@en
type
label
Circulation and degradation of GIP and GLP-1.
@ast
Circulation and degradation of GIP and GLP-1.
@en
prefLabel
Circulation and degradation of GIP and GLP-1.
@ast
Circulation and degradation of GIP and GLP-1.
@en
P356
P1476
Circulation and degradation of GIP and GLP-1.
@en
P2093
P304
P356
10.1055/S-2004-826160
P577
2004-11-01T00:00:00Z